Zentrum Fur Klinische Studien Dr. Hanusch GmbH
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Zentrum Fur Klinische Studien Dr. Hanusch GmbH in Vienna, the clinical trial portfolio is strongly focused on cardiovascular research, especially conditions linked to high risk of heart attack, stroke, and other major heart-related events. Studies are exploring new ways to reduce atherosclerotic cardiovascular disease, improve outcomes in people with elevated lipoprotein(a), and better manage broader cardiovascular disease.
- Testing new therapies aimed at lowering the risk of major cardiovascular events in people with elevated lipoprotein(a) and established heart disease risk.
- Evaluating treatments designed to prevent heart attack, stroke, and urgent coronary procedures in adults at high cardiovascular risk.
- Assessing whether newer approaches can improve cardiovascular protection beyond standard lipid-lowering care.
This area includes research on prevention as well as treatment effectiveness, with a clear goal of reducing serious complications in patients who have not yet had a prior heart attack or stroke.
Nutritional and Metabolic Diseases
The site also conducts studies in nutritional and metabolic diseases, with a particular emphasis on obesity, overweight, type 2 diabetes mellitus, and related cardiometabolic risk. These trials are examining whether newer therapies can support weight management while also improving heart and kidney outcomes.
- Investigating treatments for adults living with obesity or overweight who also face increased cardiovascular risk.
- Studying therapies for type 2 diabetes to see whether they can reduce major heart events alongside standard care.
- Exploring options that may help protect both cardiovascular and kidney health in people with metabolic disease.
Overall, the research reflects a growing focus on therapies that address both metabolic control and long-term protection against serious complications, including cardiovascular events and kidney outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Amgen Inc.2active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Zentrum Fur Klinische Studien Dr. Hanusch GmbH
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| BI 456906 | 1 | Unknown | 2024-01-08 | 2024-01-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.